Scientists believe UK jabs WILL offer major protection against South African mutation of Covid-19
Vaccine hopes on mutant strain: Scientists say they believe UK jabs WILL offer major protection against South African mutation of Covid-19
- Dr Susan Hopkins raised hopes of effectiveness of Pfizer and Oxford jabs
- Johnson & Johnson and Navavax jabs effective against South African variant
- Britain has 30 million doses of the Johnson & Johnson vaccine on order
Vaccines are not as effective against the mutant South African strain – but should still prevent serious illness and death, health chiefs said yesterday.
Dr Susan Hopkins, from Public Health England, raised hopes the Pfizer and Oxford jabs will effectively tackle the variant.
Two other vaccines – from Johnson & Johnson and Novavax – proved effective in trials in South Africa. They were found to provide around 60 per cent protection against the mutant infection, compared to almost 90 per cent for classic Covid.
Importantly, none of those infected in South Africa ended up in hospital or dead.

Vaccines are not as effective against the mutant South African strain – but should still prevent serious illness and death, health chiefs said yesterday
Dr Hopkins said: ‘We expect all other vaccines to have a similar level of effectiveness, particularly in reducing hospitalisation and death. We’re doing detailed laboratory studies at the moment with the South African variant growing in the labs, so that we will be able to estimate that with greater robustness over the next couple of weeks.’
The single-shot jab from Johnson & Johnson provided 57 per cent protection against moderate to severe Covid in the South African clinical trials. Britain has 30 million doses of the jab on order, with an option to buy 22 million more.
Meanwhile the vaccine from Novavax, which will supply 60 million doses to the UK, was found to be 60 per cent effective in preventing mild, moderate and severe Covid in its South African trial, where people did not have HIV. Both vaccines provided 100 per cent protection against hospitalisation or death.
At the weekend, Dr Hopkins described the results as ‘reassuring news’ on the BBC’s Andrew Marr Show, adding: ‘I think it’s hard to imagine how the different vaccines won’t have similar levels of effectiveness – I think they would have at least 50 per cent, maybe even more.’
Yesterday, speaking at the Downing Street press conference, she dispelled fears that people recently vaccinated would have to start over again because of the risk from new strains. Dr Hopkins said: ‘It is unlikely that people would have to start (the vaccine treatment) again, it is much more likely that it would be a booster shot – a bit like the annual flu vaccine.’

The single-shot jab from Johnson & Johnson provided 57 per cent protection against moderate to severe Covid in the South African clinical trials. Britain has 30 million doses of the jab on order, with an option to buy 22 million more

Professor Adam Finn, a member of the joint committee on vaccination and immunisation, also said yesterday that the vaccines currently deployed in the UK are likely to tackle the South African variant.
Experts had feared its mutations may cause problems for the jabs, which were designed to tackle previous strains, such as the original one which emerged in the Chinese city of Wuhan. But Professor Finn told Radio 4’s The World at One: ‘It may be the case that they are just slightly less efficient than they are against the original Wuhan virus, but that doesn’t mean that they are not useful.
‘These vaccines are much more effective than we dared hope for in the first place, so some reduction in their efficiency is not a disaster. It is just making life more difficult. We do have to recognise that we are facing a very agile enemy. We have to up our game, get better and more efficient ways of tracking these new variants as they arrive.’
Ministers are increasingly confident of hitting their target of vaccinating the 15 million most vulnerable by mid-February.
Figures show 9,790,576 Covid jabs have now been given, of which 9,296,367 were first doses. That means 407,402 first doses would be needed each day in order to meet the target of 15 million first doses by February 15.
![]()

